Equity (Details) |
1 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 10, 2022
shares
|
Jul. 01, 2022
shares
|
Jul. 08, 2020 |
May 03, 2019 |
Feb. 08, 2019
shares
|
Oct. 01, 2016 |
May 06, 2016 |
Feb. 08, 2016
shares
|
May 31, 2022
$ / shares
shares
|
Mar. 31, 2022
USD ($)
$ / shares
shares
|
Nov. 30, 2021
USD ($)
$ / shares
shares
|
Aug. 31, 2021
USD ($)
shares
|
Jul. 31, 2021
USD ($)
shares
|
Nov. 21, 2020
USD ($)
shares
|
Nov. 19, 2020
$ / shares
shares
|
Aug. 31, 2019
USD ($)
$ / shares
|
Jun. 30, 2019
USD ($)
shares
|
Feb. 28, 2017 |
Aug. 26, 2016 |
Feb. 17, 2016
shares
|
Sep. 30, 2022
USD ($)
$ / shares
shares
|
Jun. 30, 2022
USD ($)
|
Sep. 30, 2021
USD ($)
|
Jun. 30, 2022
USD ($)
|
Sep. 30, 2022
USD ($)
$ / shares
shares
|
Sep. 30, 2021
USD ($)
|
Dec. 31, 2020
USD ($)
$ / shares
shares
|
Dec. 31, 2021
USD ($)
$ / shares
shares
|
Aug. 05, 2021 |
Jun. 29, 2021
$ / shares
shares
|
May 17, 2021
$ / shares
|
Mar. 12, 2020
$ / shares
shares
|
Dec. 31, 2019
shares
|
Sep. 25, 2017
USD ($)
|
Mar. 21, 2016
$ / shares
shares
|
|
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Common stock, par value (in Dollars per share) | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||||||||||||||||||||||||
Ordinary shares authorized | 360,000,000 | ||||||||||||||||||||||||||||||||||
Agreement, description | On May 6, 2016, the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company’s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. | In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company’s Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company’s Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit). | The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. | ||||||||||||||||||||||||||||||||
Issuance of common shares, shares | 1,111,112 | ||||||||||||||||||||||||||||||||||
Financial amendment, description | On May 3, 2019, the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority (“FINRA”). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company’s common stock were exchanged for 17,693,625 shares of the Company’s Common Stock. | ||||||||||||||||||||||||||||||||||
Common stock, shares issued | 32,632,329 | 32,632,329 | 28,926,322 | 50,000 | 644,972 | ||||||||||||||||||||||||||||||
Consulting fees (in Dollars) | $ | $ 4,514,800 | ||||||||||||||||||||||||||||||||||
Stock subscription receivable (in Dollars) | $ | $ 1,580,180 | $ 1,580,180 | $ 2,257,400 | ||||||||||||||||||||||||||||||||
Due to related parties consideration (in Dollars) | $ | $ 4,872,340 | ||||||||||||||||||||||||||||||||||
Common stock price per share (in Dollars per share) | $ / shares | $ 7 | $ 2.25 | |||||||||||||||||||||||||||||||||
Common stock, authorized | 100,000,000 | 100,000,000 | 100,000,000 | ||||||||||||||||||||||||||||||||
Consulting and advisory services value per share (in Dollars per share) | $ / shares | $ 2.26 | $ 5 | |||||||||||||||||||||||||||||||||
Warrant issued | 200,000 | ||||||||||||||||||||||||||||||||||
Exercise price (in Dollars per share) | $ / shares | $ 2.25 | ||||||||||||||||||||||||||||||||||
Warrant term | 5 years | ||||||||||||||||||||||||||||||||||
Issuance of common stock | 3,384,615 | ||||||||||||||||||||||||||||||||||
Aggregate common stock shares | 673,605 | 915,856 | |||||||||||||||||||||||||||||||||
Convertible promissory note value (in Dollars) | $ | $ 2,500,000 | ||||||||||||||||||||||||||||||||||
Description of public offering | On August 5, 2021, the Company closed its public offering (the “Public Offering”) of 1,100,000 units (the “Units”), with each Unit consisting of one share of the Company’s common stock, one Series A warrant (the “Series A Warrants”) to purchase one share of common stock at an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the “Series B Warrants,” and together with the Series A Warrants, the “Public Warrants”) to purchase one share of common stock at an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the “SEC”) on April 8, 2021 (as amended, the “Original Registration Statement”), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the “S-1MEF,” together with the Original Registration Statement, the “Registration Statement”). The Units were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000. | ||||||||||||||||||||||||||||||||||
Issuance of common stock for debt (in Dollars) | $ | $ 3,917,425 | $ 6,875,000 | |||||||||||||||||||||||||||||||||
Gross proceeds from exercise of warrants (in Dollars) | $ | $ 4,244,452 | ||||||||||||||||||||||||||||||||||
Consulting agreement desciption | In November 2021, the Company entered into consulting agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted $1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant date. These shares have been issued during the year ended December 31, 2021. In January 2022, the Company agreed to pay the deferred service fees related to Public Offering amounted $4,296,763 by issuing 1,306,007 shares of unrestricted common shares, valued at $3.29 per share on the grant date. These shares have been issued in January 2022. | ||||||||||||||||||||||||||||||||||
Common shares, issued | 75,000 | ||||||||||||||||||||||||||||||||||
Consulting and advisory services amount (in Dollars) | $ | $ 169,500 | 556,075 | |||||||||||||||||||||||||||||||||
Shares issued | 2,000,000 | ||||||||||||||||||||||||||||||||||
Common stock issued of gross proceeds (in Dollars) | $ | $ 253,500 | $ 3,663,925 | $ 6,024,571 | $ 4,220,000 | |||||||||||||||||||||||||||||||
Warrants term | 5 years | ||||||||||||||||||||||||||||||||||
Shares of common stock | 2,000,000 | ||||||||||||||||||||||||||||||||||
Exercisable price per share (in Dollars per share) | $ / shares | $ 2.45 | $ 2.45 | |||||||||||||||||||||||||||||||||
2016 Equity Incentive Plan [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Common stock issued post-stock split | 157,050 | ||||||||||||||||||||||||||||||||||
Common stock issued pre-stock split | 50,000 | ||||||||||||||||||||||||||||||||||
Share Exchange Agreement Two [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Ownership percentage | 79.70% | ||||||||||||||||||||||||||||||||||
Private Placement [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Aggregated capital contributions (in Dollars) | $ | $ 7,615,331 | ||||||||||||||||||||||||||||||||||
Number of investors | 45 | ||||||||||||||||||||||||||||||||||
Purchase price per share (in Dollars per share) | $ / shares | $ 2.25 | ||||||||||||||||||||||||||||||||||
IPO [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Common stock issued to professional investors | 2,354,145 | ||||||||||||||||||||||||||||||||||
Issuance of common stock for debt (in Dollars) | $ | $ 6,875,000 | ||||||||||||||||||||||||||||||||||
Legal fees (in Dollars) | $ | $ 850,429 | ||||||||||||||||||||||||||||||||||
Series A Warrants [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Warrants exercised | 673,405 | ||||||||||||||||||||||||||||||||||
Warrants exercise price (in Dollars per share) | $ / shares | $ 6.3 | ||||||||||||||||||||||||||||||||||
Series B Warrants [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Warrants exercised | 200 | ||||||||||||||||||||||||||||||||||
Warrants exercise price (in Dollars per share) | $ / shares | $ 10 | ||||||||||||||||||||||||||||||||||
Common Stock [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Offering per share (in Dollars per share) | $ / shares | $ 2.11 | ||||||||||||||||||||||||||||||||||
Kameyama [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Issuance of common shares, shares | 24,694 | ||||||||||||||||||||||||||||||||||
Unpaid consulting fees (in Dollars) | $ | $ 49,388 | ||||||||||||||||||||||||||||||||||
Articles of Incorporation [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Common stock, par value (in Dollars per share) | $ / shares | $ 0.001 | ||||||||||||||||||||||||||||||||||
Articles of Incorporation [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Common stock, authorized | 20,000,000 | ||||||||||||||||||||||||||||||||||
Articles of Incorporation [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Common stock, authorized | 100,000,000 | ||||||||||||||||||||||||||||||||||
View Trade Securities Inc. [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Common stock, shares issued | 60,000 | ||||||||||||||||||||||||||||||||||
Consulting fees (in Dollars) | $ | $ 135,000 | ||||||||||||||||||||||||||||||||||
Placement agent agreement, description | Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years with cashless exercise provision. | ||||||||||||||||||||||||||||||||||
Restricted common shares | 6,000 | ||||||||||||||||||||||||||||||||||
WallachBeth Capital LLC [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Shares issued | 6,000 | ||||||||||||||||||||||||||||||||||
Consulting Agreement [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Common stock price per share (in Dollars per share) | $ / shares | $ 2.9 | ||||||||||||||||||||||||||||||||||
Unrestricted common shares | 50,000 | ||||||||||||||||||||||||||||||||||
Non Related Parties [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt conversion, description | a.Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company’s common stock, and warrants to purchase 159,145 shares of the Company’s common stock. b. Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company’s common stock, and warrants to purchase 154,368 shares of the Company’s common stock. c. C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company’s common stock, and warrants to purchase 162,908 shares of the Company’s common stock. d. KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company’s common stock, and warrants to purchase 126,530 shares of the Company’s common stock. e. Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company’s common stock, and warrants to purchase 192,784 shares of the Company’s common stock. f. KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company’s common stock, and warrants to purchase 120,121 shares of the Company’s common stock. | ||||||||||||||||||||||||||||||||||
Barlew Holdings, LLC [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Shares of common stock | 75,000 | ||||||||||||||||||||||||||||||||||
Inverlew Advisors, LLC [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Shares of common stock | 250,000 | ||||||||||||||||||||||||||||||||||
BioLite [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Issuance of common shares, shares | 74,997,546 | ||||||||||||||||||||||||||||||||||
BioKey [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Common stock issued post-stock split | 1,642,291 | ||||||||||||||||||||||||||||||||||
Issuance of common shares, shares | 29,561,231 | ||||||||||||||||||||||||||||||||||
Share Exchange Agreement [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Common stock issued post-stock split | 164,387,376 | ||||||||||||||||||||||||||||||||||
Common stock issued pre-stock split | 52,336,000 | ||||||||||||||||||||||||||||||||||
Share Exchange Agreement One [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Common stock issued post-stock split | 166,273,921 | ||||||||||||||||||||||||||||||||||
Common stock issued pre-stock split | 52,936,583 | ||||||||||||||||||||||||||||||||||
Share Exchange Agreement Two [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Common stock issued post-stock split | 163,159,952 | ||||||||||||||||||||||||||||||||||
Common stock issued pre-stock split | 51,945,225 | ||||||||||||||||||||||||||||||||||
Percentage of issued share capital | 100.00% | ||||||||||||||||||||||||||||||||||
Share Exchange Agreement Three [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Common stock issued post-stock split | 166,273,921 | ||||||||||||||||||||||||||||||||||
Common stock issued pre-stock split | 52,936,583 | ||||||||||||||||||||||||||||||||||
Share Exchange Agreement Four [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Common stock issued post-stock split | 205,519,223 | ||||||||||||||||||||||||||||||||||
Common stock issued pre-stock split | 65,431,144 | ||||||||||||||||||||||||||||||||||
Collaborative Arrangement [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Issuance of common shares, shares | 428,571 | ||||||||||||||||||||||||||||||||||
Consulting agreement, description | On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (“Kameyama”) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s Common Stock at $1.00 per share for any amount exceeding $3,000. | ||||||||||||||||||||||||||||||||||
Issuance of common shares (in Dollars) | $ | $ 3,000,000 | ||||||||||||||||||||||||||||||||||
Co-Dev Agreement [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Due to related parties (in Dollars) | $ | $ 3,000,000 | ||||||||||||||||||||||||||||||||||
Consulting Agreement [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Shares issued | 521,887 | ||||||||||||||||||||||||||||||||||
Consulting Agreement [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Price per share (in Dollars per share) | $ / shares | $ 2 | ||||||||||||||||||||||||||||||||||
Consulting Agreement [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||
Equity (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Price per share | 3.68 |